Why the study?
Truncated rotavirus VP4 conferred high protection in mice, but whether its immunogenicity could be further improved by polymerization remained to be evaluated.
Does VP4 polymerization improve immunogenicity and protective efficacy against rotavirus in a mouse model?
Does VP4 polymerization improve immunogenicity and protective efficacy against rotavirus in a mouse model?
VP4 polymerization improves immunogenicity and protective efficacy against rotavirus in a mouse model, offering a potential strategy for recombinant rotavirus vaccine development.
Polymerization improves VP4 immunogenicity; leaves open translation to rotavirus vaccines.
In previous studies, we found that truncated rotavirus VP4* (aa 26-476) could be expressed in soluble form in Escherichia coli and confer high protection against rotavirus in the mouse mode. In this study, we further improved the immunogenicity of VP4* by polymerization. The purified VP4* was polymerized through incubation at 37 ℃ for 24 h, and then the homogeneity of the particles was analyzed by HPLC, TEM and AUC, while the thermal stability and antigenicity was analyzed by DSC and ELISA, respectively. Finally, the immunogenicity and protective efficacy of the polymers analyzed by a mouse maternal antibody model. The results showed that VP4* aggregated into homogeneous polymers, with high thermostability and neutralizing antibody binding activity. In addition, VP4* polymers (endotoxin <20 EU/dose) stimulated higher neutralizing antibodies and confer higher protection against rotavirus-induced diarrhoea compared with the VP4* trimers when immunized with aluminium adjuvant. In summary, the study in VP4* polymers provides a new strategy for the development of recombinant rotavirus vaccines.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: